DDInter134 DDInter905
Atovaquone is a hydroxynaphthoquinone, or an analog of ubiquinone, that has antimicrobial and antipneumocystis activity. It is being used in antimalarial protocols.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acarbose
Acarbose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Mazindol
Mazindol {u} (Compound) resembles {v} (Compound) Haloperidol
Haloperidol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Azelastine
Azelastine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may lead to a major life threatening interaction when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Phenindione
Phenindione {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Mercaptopurine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Atovaquone {u} (Compound) resembles {v} (Compound) Phenindione
Phenindione {u} (Compound) resembles {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Atovaquone {u} (Compound) binds {v} (Gene) DHODH
DHODH {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Atovaquone {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atovaquone (Compound) resembles Mazindol (Compound) and Mazindol (Compound) resembles Haloperidol (Compound) and Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Atovaquone (Compound) resembles Azelastine (Compound) and Azelastine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Idelalisib
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atovaquone (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atovaquone (Compound) resembles Anisindione (Compound) and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Atovaquone (Compound) resembles Phenindione (Compound) and Phenindione (Compound) resembles Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Atovaquone (Compound) binds DHODH (Gene) and DHODH (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Idelalisib
Atovaquone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Idelalisib